Androgens and prostate cancer

[1]  U. Jonas,et al.  Rejuvenation in the early 20th century , 2009, Andrologia.

[2]  H. Schneider.  Androgens and Antiandrogens , 2003, Annals of the New York Academy of Sciences.

[3]  K. Grigor,et al.  Androgen receptor gene amplification and protein expression in hormone refractory prostate cancer , 2003, British Journal of Cancer.

[4]  M. Gleave,et al.  Castration-induced increases in insulin-like growth factor-binding protein 2 promotes proliferation of androgen-independent human prostate LNCaP tumors. , 2003, Cancer research.

[5]  E. Bissonette,et al.  Constitutive activation of the Ras/mitogen-activated protein kinase signaling pathway promotes androgen hypersensitivity in LNCaP prostate cancer cells. , 2003, Cancer research.

[6]  O. Halvorsen,et al.  Combined loss of PTEN and p27 expression is associated with tumor cell proliferation by Ki-67 and increased risk of recurrent disease in localized prostate cancer. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[7]  M. Gleave,et al.  Resistance to cytotoxic chemotherapy-induced apoptosis in human prostate cancer cells is associated with intracellular clusterin expression. , 2003, Oncology reports.

[8]  J. Bartlett,et al.  Amplification of the androgen receptor gene in bone metastases from hormone‐refractory prostate cancer , 2002, The Journal of pathology.

[9]  M. Gleave,et al.  Intermittent androgen suppression in prostate cancer: the Canadian experience. , 2002, Urology.

[10]  N. Bruchovsky,et al.  Activation of the Androgen Receptor N-terminal Domain by Interleukin-6 via MAPK and STAT3 Signal Transduction Pathways* , 2002, The Journal of Biological Chemistry.

[11]  M. Gleave,et al.  Clusterin expression is significantly enhanced in prostate cancer cells following androgen withdrawal therapy , 2002, The Prostate.

[12]  J. Graff.  Emerging targets in the AKT pathway for treatment of androgen-independent prostatic adenocarcinoma , 2002, Expert opinion on therapeutic targets.

[13]  D. Neal,et al.  Expression of RAC 3, a steroid hormone receptor co-activator in prostate cancer , 2001, British Journal of Cancer.

[14]  S. Groshen,et al.  Her-2/neu expression in prostate cancer: high level of expression associated with exposure to hormone therapy and androgen independent disease. , 2001, The Journal of urology.

[15]  D. Feldman,et al.  The development of androgen-independent prostate cancer , 2001, Nature Reviews Cancer.

[16]  F. S. French,et al.  A mechanism for androgen receptor-mediated prostate cancer recurrence after androgen deprivation therapy. , 2001, Cancer research.

[17]  R L Vessella,et al.  Advances in Brief Amplification and Overexpression of Androgen Receptor Gene in Hormone-Refractory Prostate Cancer 1 , 2001 .

[18]  F. S. French,et al.  Androgen receptor stabilization in recurrent prostate cancer is associated with hypersensitivity to low androgen. , 2001, Cancer research.

[19]  O. Cussenot,et al.  Evaluation of androgen, estrogen (ER alpha and ER beta), and progesterone receptor expression in human prostate cancer by real-time quantitative reverse transcription-polymerase chain reaction assays. , 2001, Cancer research.

[20]  E. McGuire,et al.  A brief history of testosterone. , 2001, The Journal of urology.

[21]  M. Namiki,et al.  ADRENAL STEROIDS IN HUMAN PROSTATIC CANCER CELL LINES , 2001, Archives of andrology.

[22]  K. Makino,et al.  HER-2/neu promotes androgen-independent survival and growth of prostate cancer cells through the Akt pathway. , 2000, Cancer research.

[23]  J. Manola,et al.  Her-2-neu expression and progression toward androgen independence in human prostate cancer. , 2000, Journal of the National Cancer Institute.

[24]  T. Tammela,et al.  Androgen receptor gene amplification at primary progression predicts response to combined androgen blockade as second line therapy for advanced prostate cancer. , 2000, The Journal of urology.

[25]  Honglin Zhou,et al.  Akt Regulates Cell Survival and Apoptosis at a Postmitochondrial Level , 2000, The Journal of cell biology.

[26]  A Rostagno,et al.  Apolipoprotein J (clusterin) and Alzheimer's disease , 2000, Microscopy research and technique.

[27]  C. Petito,et al.  Overexpression of clusterin in human breast carcinoma. , 2000, The American journal of pathology.

[28]  E. Jaffe,et al.  Detection of differentially expressed genes in lymphomas using cDNA arrays: identification of clusterin as a new diagnostic marker for anaplastic large-cell lymphomas. , 2000, Blood.

[29]  B. Calabretta,et al.  Direct Transactivation of the Anti-apoptotic Gene Apolipoprotein J (Clusterin) by B-MYB* , 2000, The Journal of Biological Chemistry.

[30]  Donna M. Peehl,et al.  Glucocorticoids can promote androgen-independent growth of prostate cancer cells through a mutated androgen receptor , 2000, Nature Medicine.

[31]  M. Gleave,et al.  Castration-induced up-regulation of insulin-like growth factor binding protein-5 potentiates insulin-like growth factor-I activity and accelerates progression to androgen independence in prostate cancer models. , 2000, Cancer research.

[32]  H. Miyake,et al.  Acquisition of chemoresistant phenotype by overexpression of the antiapoptotic gene testosterone-repressed prostate message-2 in prostate cancer xenograft models. , 2000, Cancer research.

[33]  P. Cohen,et al.  Role of insulin‐like growth factors and their binding proteins in growth control and carcinogenesis , 2000, Journal of cellular physiology.

[34]  M. Hung,et al.  HER-2/neu Blocks Tumor Necrosis Factor-induced Apoptosis via the Akt/NF-κB Pathway* , 2000, The Journal of Biological Chemistry.

[35]  M. Wilson,et al.  Clusterin is a secreted mammalian chaperone. , 2000, Trends in biochemical sciences.

[36]  P. Cohen,et al.  Prostatic involution in men taking finasteride is associated with elevated levels of insulin‐like growth factor‐binding proteins (IGFBPs)‐2, ‐4, and ‐5 , 2000, The Prostate.

[37]  J. Eastham,et al.  Androgen receptor mutations in prostate cancer. , 2000, Cancer research.

[38]  J. Schleutker,et al.  Androgen receptor gene alterations and chromosomal gains and losses in prostate carcinomas appearing during finasteride treatment for benign prostatic hyperplasia. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[39]  E Mahlamäki,et al.  Hormone therapy failure in human prostate cancer: analysis by complementary DNA and tissue microarrays. , 1999, Journal of the National Cancer Institute.

[40]  A. Belldegrun,et al.  Evidence for clonal outgrowth of androgen-independent prostate cancer cells from androgen-dependent tumors through a two-step process. , 1999, Cancer research.

[41]  E. Small,et al.  Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist. , 1999, Cancer research.

[42]  J. Isaacs,et al.  The biology of hormone refractory prostate cancer. Why does it develop? , 1999, The Urologic clinics of North America.

[43]  R. Roth,et al.  Modulation of Insulin Receptor Substrate-1 Tyrosine Phosphorylation by an Akt/Phosphatidylinositol 3-Kinase Pathway* , 1999, The Journal of Biological Chemistry.

[44]  M. S. Khan,et al.  Sex hormone-binding globulin mediates steroid hormone signal transduction at the plasma membrane , 1999, The Journal of Steroid Biochemistry and Molecular Biology.

[45]  S. Inui,et al.  Cloning and Characterization of Androgen Receptor Coactivator, ARA55, in Human Prostate* , 1999, The Journal of Biological Chemistry.

[46]  J. Carver,et al.  Clusterin Has Chaperone-like Activity Similar to That of Small Heat Shock Proteins* , 1999, The Journal of Biological Chemistry.

[47]  Noah Craft,et al.  A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase , 1999, Nature Medicine.

[48]  Desok Kim,et al.  Androgen receptor expression in androgen-independent prostate cancer is associated with increased expression of androgen-regulated genes. , 1998, Cancer research.

[49]  D. Bostwick,et al.  Independent origin of multiple foci of prostatic intraepithelial neoplasia , 1998, Cancer.

[50]  H. Klocker,et al.  Interleukin-6 regulates prostate-specific protein expression in prostate carcinoma cells by activation of the androgen receptor. , 1998, Cancer research.

[51]  W. Kelly.  Endocrine Withdrawal Syndrome and Its Relevance to the Management of Hormone Refractory Prostate Cancer , 1998, European Urology.

[52]  I. Leav,et al.  Lack of association between enhanced TRPM-2/clusterin expression and increased apoptotic activity in sex-hormone-induced prostatic dysplasia of the Noble rat. , 1998, The American journal of pathology.

[53]  G. Wilding,et al.  Promotion of agonist activity of antiandrogens by the androgen receptor coactivator, ARA70, in human prostate cancer DU145 cells. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[54]  K. Nath,et al.  Clusterin protects against oxidative stress in vitro through aggregative and nonaggregative properties. , 1998, Kidney international.

[55]  S. North,et al.  Stress-induced transcription of the clusterin/apoJ gene. , 1997, The Biochemical journal.

[56]  A. Rademaker,et al.  Intracellular levels of SGP-2 (Clusterin) correlate with tumor grade in prostate cancer. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[57]  G. Bubley,et al.  Functional characterization of mutant androgen receptors from androgen-independent prostate cancer. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[58]  H. Klocker,et al.  Synergistic activation of androgen receptor by androgen and luteinizing hormone‐releasing hormone in prostatic carcinoma cells , 1997, The Prostate.

[59]  A. Klippel,et al.  Antiapoptotic signalling by the insulin-like growth factor I receptor, phosphatidylinositol 3-kinase, and Akt , 1997, Molecular and cellular biology.

[60]  T. McDonnell,et al.  Expression of bcl-2 oncoprotein and p53 protein accumulation in bone marrow metastases of androgen independent prostate cancer. , 1997, The Journal of urology.

[61]  H. Daniell.  Osteoporosis after orchiectomy for prostate cancer. , 1997, The Journal of urology.

[62]  S. Graham,et al.  Bone fractures associated with luteinizing hormone‐releasing hormone agonists used in the treatment of prostate carcinoma , 1997, Cancer.

[63]  P. Schellhammer,et al.  A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone–Releasing hormone analogue therapy, in patients with advanced prostate carcinoma: Analysis of time to progression , 1996, Cancer.

[64]  K. Akakura,et al.  Codon 877 Mutation in the Androgen Receptor Gene in Advanced Prostate Cancer: Relation to Antiandrogen Withdrawal Syndrome , 1996, The Prostate.

[65]  C. M. Wilson,et al.  A and B forms of the androgen receptor are expressed in a variety of human tissues , 1996, Molecular and Cellular Endocrinology.

[66]  M. Gleave,et al.  Low-dose cyproterone acetate plus mini-dose diethylstilbestrol--a protocol for reversible medical castration. , 1996, Urology.

[67]  S. Yeh,et al.  Cloning and characterization of a specific coactivator, ARA70, for the androgen receptor in human prostate cells. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[68]  E. Crawford,et al.  Estrogens in the treatment of prostate cancer. , 1995, The Journal of urology.

[69]  H. Perlman,et al.  Overexpression of bcl-2 protects prostate cancer cells from apoptosis in vitro and confers resistance to androgen depletion in vivo. , 1995, Cancer research.

[70]  H. Rao.  Maximum androgen blockade in advanced prostate cancer: an overview of 22 randomised trials with 3283 deaths in 5710 patients , 1995, The Lancet.

[71]  O. Dalesio,et al.  MAXIMUM ANDROGEN BLOCKADE IN ADVANCED PROSTATE-CANCER - AN OVERVIEW OF 22 RANDOMIZED TRIALS WITH 3283 DEATHS IN 5710 PATIENTS , 1995 .

[72]  M E Rosenberg,et al.  Clusterin: physiologic and pathophysiologic considerations. , 1995, The international journal of biochemistry & cell biology.

[73]  M. Griswold,et al.  Prevention of cell death induced by tumor necrosis factor alpha in LNCaP cells by overexpression of sulfated glycoprotein-2 (clusterin). , 1995, Cancer research.

[74]  G. Bubley,et al.  Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. , 1995, The New England journal of medicine.

[75]  Jorma Isola,et al.  In vivo amplification of the androgen receptor gene and progression of human prostate cancer , 1995, Nature Genetics.

[76]  D. Clemmons,et al.  Insulin-like growth factors and their binding proteins: biological actions. , 1995, Endocrine reviews.

[77]  H. Klocker,et al.  Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor and epidermal growth factor. , 1995, European urology.

[78]  R. Tattersall.  Charles‐Edouard Brown‐Séquard: Double‐hyphenated Neurologist and Forgotten Father of Endocrinology , 1994, Diabetic medicine : a journal of the British Diabetic Association.

[79]  D. Peehl,et al.  Biological effects of prostate specific antigen as an insulin-like growth factor binding protein-3 protease. , 1994, The Journal of endocrinology.

[80]  Schr,et al.  Androgen receptor status in localized and locally progressive hormone refractory human prostate cancer. , 1994, The American journal of pathology.

[81]  D. Peehl,et al.  The IGF axis in the prostate. , 1994, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[82]  H. Klocker,et al.  Mutant androgen receptor detected in an advanced-stage prostatic carcinoma is activated by adrenal androgens and progesterone. , 1993, Molecular endocrinology.

[83]  L. French,et al.  Distinct sites of production and deposition of the putative cell death marker clusterin in the human thymus. , 1992, The Journal of clinical investigation.

[84]  J. Welsh,et al.  Active cell death in hormone-dependent tissues , 1992, Cancer and Metastasis Reviews.

[85]  W. Isaacs,et al.  Androgen receptor gene mutations in human prostate cancer. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[86]  G. Jenster,et al.  The androgen receptor in LNCaP cells contains a mutation in the ligand binding domain which affects steroid binding characteristics and response to antiandrogens , 1992, The Journal of Steroid Biochemistry and Molecular Biology.

[87]  A. Benabid,et al.  Human gliomas and epileptic foci express high levels of a mRNA related to rat testicular sulfated glycoprotein 2, a purported marker of cell death. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[88]  C. Olsson,et al.  SGP-2 expression as a genetic marker of progressive cellular pathology in experimental hydronephrosis. , 1991, Kidney international.

[89]  B. Setchell,et al.  The testis and tissue transplantation: historical aspects. , 1990, Journal of reproductive immunology.

[90]  P. Goodman,et al.  A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. , 1989, The New England journal of medicine.

[91]  N. Bruchovsky,et al.  The conversion of testosterone to 5-alpha-androstan-17-beta-ol-3-one by rat prostate in vivo and in vitro. , 1968, The Journal of biological chemistry.

[92]  C. Huggins,et al.  Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate , 1941, CA: a cancer journal for clinicians.

[93]  C. Pilarsky,et al.  Gp80 (clusterin; TRPM-2) mRNA level is enhanced in human renal clear cell carcinomas , 2005, Journal of Cancer Research and Clinical Oncology.

[94]  N. Bruchovsky.  The Conversion of Testosterone to 5 ~-Androstan-17 ~-ol-3-one by Rat Prostate in Viwo and in Vitro * , 2003 .

[95]  T. H. van der Kwast,et al.  Androgen‐independent growth is induced by neuropeptides in human prostate cancer cell lines , 2000, The Prostate.

[96]  M. C. Hu,et al.  HER-2/neu blocks tumor necrosis factor-induced apoptosis via the Akt/NF-kappaB pathway. , 2000, The Journal of biological chemistry.

[97]  H. Miyake,et al.  Testosterone-repressed prostate message-2 is an antiapoptotic gene involved in progression to androgen independence in prostate cancer. , 2000, Cancer research.

[98]  U. Jonas,et al.  Tissue engineering from Adam to the zygote: historical reflections , 2000, World Journal of Urology.

[99]  C. Morgans,et al.  Clusterin: a role in cell survival in the face of apoptosis? , 1996, Progress in molecular and subcellular biology.

[100]  G. Blackledge,et al.  High-dose bicalutamide monotherapy for the treatment of prostate cancer. , 1996, Urology.

[101]  P. Schellhammer,et al.  A controlled trial of Casodex (bicalutamide) vs. flutamide, each in combination with luteinising hormone-releasing hormone analogue therapy in patients with advanced prostate cancer. Casodex Combination Study Group. , 1996, European urology.

[102]  M. Rosenberg,et al.  Clusterin and the kidney. , 1995, Experimental nephrology.

[103]  B. O’Malley,et al.  Molecular mechanisms of action of steroid/thyroid receptor superfamily members. , 1994, Annual review of biochemistry.

[104]  R. Matusik,et al.  Characterization of two cis-acting DNA elements involved in the androgen regulation of the probasin gene. , 1993, Molecular endocrinology.

[105]  N. Davidson,et al.  Programmed cell death during regression of the MCF-7 human breast cancer following estrogen ablation. , 1991, Cancer research.

[106]  M. Tenniswood,et al.  Androgen‐repressed messages in the rat ventral prostate , 1986, The Prostate.